“a bio composite scaffold composition and method for preparation thereof”
Patent Information
- Application Number
- IN202521043138
- Authority / Receiving Office
- IN · IN
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2025-05-04
- Publication Date
- 2026-10-26
- Estimated Expiration
- 2045-05-04
AI Technical Summary
Existing wound dressings based on allantoin lack stability and have defects such as fragility and poor extensibility, while traditional alternatives like ointments and creams have insufficient interaction time with the wound surface.
A biocomposite scaffold composition is developed, comprising chitosan, gelatin, allantoin, and glycerol, which is fabricated through solution casting. The allantoin is extracted from Bacillus subtilis broth using an optimized fermentation method and integrated into the scaffold matrix.
The biocomposite scaffold exhibits improved antibacterial activity, enhanced wound healing properties, and increased stability, making it suitable for wound dressing applications.
Abstract
Description
TECHNICAL FIELD
[0001] The present invention relates to the field of microbiology, biochemistry, pharmacology and medicine. More particularly, it concerns antimicrobial compositions of scaffold for wound healing application.BACKGROUND ART
[0001] Background description includes information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, or that any publication specifically or implicitly referenced is prior art.
[0002] The developmental phases of materials science and biomedicine, skin wound dressings have changed significantly. Traditional dressings viz. medical absorbent cotton gauze, cotton balls, Vaseline gauze cannot meet the requirements of patients on wound care; therefore, it is need to fabricate new wound dressings which will actively used in clinics. With the advent and development of new wound dressings, natural flexible polymers are introduced in more and more tissue engineering fields. Although wound dressings based on allantoin, biopolymers are highly favoured by biomedical engineering and materials researchers. Along with dressing applications, allantoin has been present in oral mucosal injury drug products for use as oral wound healing agents.
[0003] Oral wound healing agents have been marketed as aids in the healing of minor oral wounds by means other than cleansing and irrigating, or by serving as a protectant. Allantoin is a commonly used ingredient in cosmetic applications, particularly for skin creams, where it exerts a skin protective function. Many such cosmetic compositions and other compositions are prepared as bandage material, particularly allantoin containing scaffold. Because cosmetics and other preparations designed for application to the skin are typically stored by users at room temperature, and room temperatures can fluctuate with climatic conditions. Its degree of stability is undesirable and have uncertain exposure time. Therefore, there is a need for a scaffold composition containing allantoin in which the stability of allantoin is increased. A dressing based solely on allantoin which can meet all the requirements of an ideal wound dressing has not been provided for a while, and has certain defects such as greater fragility, poorer extensibility and the like.
[0004] The traditional alternatives for wound healing such as ointments, lotions and creams are insignificant due to insufficient interaction time with surface of wound along with indefinite dosage. The usage of biopolymer assisted hydrogels, biogels, nanoporous material, thin films embedded with drug material and antibacterial agent is an admirable technique to overcome the classical methods of wound dressing. The standard healing material should support cell proliferation and regeneration of new tissues. Synthesis of new healing material by using biopolymers like alginate, gelatine, dextran, heparin, chitosan and some protein compounds like keratin, collagen will be added advantage due to their biocompatible and biodegradable nature. Chitosan a natural biopolymer is famous for its affinity towards red blood cells and well known for blood clotting activity. It is approved by USA regulations as a hemostatic agent in wound dressing materials and more important it helps at each step of healing process.
[0005] Gelatine, another material for wound dressing is well approached compound for its activities viz cell adhesion, proliferation and migration. Previous literature studies reported that gelatine aid to blood coagulation during surgical operations. Both the gelatine and chitosan possess film-forming ability. Owing to the features of chitosan and gelatine, it is extensively applied in drug delivery and wound dressing compositions. Therefore, blending of such biopolymers, added with drug molecules will impressive approach for implementation of wound dressing material.
[0006] To address some of the disadvantages of a single polymer, it is often chosen to blend it with another polymer to meet the requirements of material complexity. The advantages of biopolymers based allantoin impregnated scaffold are high speed of repairing wound surface, less infection of wound and short course of disease. Based on this background, the development of multifunctional new skin dressings is becoming a research focus in the medical and materials fields. It has the characteristics of high mechanical strength, good elasticity, excellent biocompatibility, biodegradability. So this scaffold is very suitable for preparing artificial skin; in addition to materials such as films, gels, microspheres, porous scaffolds through different preparation modes such as electrospinning, salting out, ultrasonic treatment, freeze drying etc.
[0007] A biopolymers like, chitosan and gelatine are a natural polysaccharide compound with good biocompatibility, low cost, and no toxicity. The substances are rapidly combined and form gel-like substances, and the gel-like substances are widely applied to tissue engineering. The biopolymers-based dressing prepared by ionic crosslinking is easy to fold and apply and has good moisture absorption performance. The substances are rapidly combined and form gel-like substances, and the gel-like substances are widely applied to tissue engineering. Because a single biological material has inherent defects more or less, the composite biological dressing is a great trend for developing novel biological dressings; In particular, there is a need for compositions that are suitable for treating a number of severe and difficult-to-treat skin conditions. One of these skin conditions is epidermolysis bullosa. This is a severe genetic skin disorder in which the skin breaks down and large blisters appear. These blisters are difficult to treat by conventional means. Other skin diseases for which improved treatments are needed are pressure ulcers, decubitus ulcers or bed sores, and diabetic ulcers, as well as milia. Therefore, improved compositions that are suitable for treating these diseases are needed.
[0008] Scaffolds for Wound Healing Applications. In order to overcome the shortcomings related to unspecific and partially efficient conventional wound dressings, impressive efforts are oriented in the development and evaluation of new and effective platforms for wound healing applications. In situ formed wound dressings provide several advantages, including proper adaptability for wound bed microstructure and architecture, facile application, patient compliance and enhanced therapeutic effects. Natural or synthetic, composite or hybrid biomaterials represent suitable candidates for accelerated wound healing, by providing proper air and water vapor permeability, structure for macro- and microcirculation, support for cellular migration and proliferation, protection against microbial invasion and external contamination. Besides being the most promising choice for wound care applications, polymeric biomaterials (either from natural or synthetic sources) may exhibit intrinsic wound healing properties. Several nanotechnology-derived biomaterials proved great potential for wound healing applications, including micro- and nanoparticulate systems, fibrous scaffolds, and hydrogels. The present paper comprises the most recent data on modern and performant strategies for effective wound healing.
[0009] US11096997B2 A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated into or coated onto the scaffold composition such that the scaffold composition and / or a bioactive composition controls egress of a resident cell or progeny thereof. The devices mediate active recruitment, modification, and release of host cells from the material.
[0010] While there are indeed several alternative ways to approach the problem of treating neurodegenerative disorders with antioxidant compounds, each alternative would require significant research and development. The specific advantages of using a gel formulation with ferulic acid and gamma-cyclodextrin-such as improved stability, bioavailability, and targeted delivery-present a strong case for this particular invention. However, other innovative solutions could potentially be developed, though they would involve different scientific and technical challenges.OBJECTS OF THE INVENTION
[0010] The primary objective of the present invention is a biocomposite film composed of biopolymers chitosan (CS), gelatin (GE) and allantoin (AT) was fabricated through solution casting technique
[0011] Another objective of the present invention is to extract the microbial allantoin from the broth of Bacillus subtilis.
[0012] Another objective of the present invention is to estimate the allantoin by spectrophotometric methods.
[0013] Another objective of the present invention is to characterize the extracted allantoin by various spectroscopic and chromatographic methods.
[0014] Another objective of the present invention is to synthesize and optimize the scaffold preparation.
[0015] Another objective of the present invention is to study physicochemical properties of extracted allantoin and scaffold development.
[0016] Another objective of the present invention is to check antibacterial activity of synthesized allantoin scaffold used in dressing materials and compare its efficacy with standard bandage.
[0017] Another objective of the present invention is to check cell viability and cell proliferation studies of microbial allantoin scaffold on (L929) fibroblast cell lines.
[0018] Yet another objective of the present invention is to provide a novel biocomposite scaffold composition comprising chitosan, gelatin, allantoin, and glycerol, designed for biomedical or pharmaceutical applications with enhanced biocompatibility and regenerative properties.
[0019] Another objective of the present invention is to develop an optimized fermentation-based method for the production of allantoin using Bacillus subtilis SP6, with a specifically formulated culture medium for improved yield and purity.
[0020] Another objective of the present invention is to establish a cost-effective and efficient extraction and purification process for allantoin involving methanol-based extraction, overnight precipitation, and rotary evaporation for concentration.
[0021] Another objective of the present invention is to integrate the purified allantoin into the biocomposite scaffold matrix, enhancing the functional properties of the scaffold for potential wound healing, tissue engineering, or drug delivery applications.
[0022] Another objective of the present invention is to optimize the preparation ratios of chitosan and gelatin (e.g., 1:3, 1:1, 3:1) for scaffold formation and evaluate the impact of allantoin addition on the physical and chemical properties of the resulting composite material.
[0023] Another objective of the present invention is to demonstrate the utility of glycerol as a plasticizer in the scaffold matrix to improve flexibility and handling characteristics of the dried biocomposite.
[0024] Another objective of the present invention is to provide a scalable and reproducible method for simultaneous production and incorporation of biologically active allantoin into a biopolymer scaffold, maintaining the functional integrity of both the scaffold and the active compound.SUMMARY
[0025] The present invention relates generally to the field of microbiology, biochemistry, pharmacology and medicine. More particularly, it concerns to an antimicrobial composition of scaffold for wound healing application.
[0026] According to an embodiment of the present invention, it relates to a bio composite scaffold composition, comprising: i) chitosan at a concentration of 1% w / v dissolved in 1% v / v acetic acid; ii) gelatin at a concentration of 10% w / v dissolved in double distilled water; iii) allantoin in the amount of 0.5% w / v; and iv) glycerol in the amount of 2 ml per 100 ml of the final mixture.
[0027] According to another embodiment of the present invention the method for the preparation of allantoin production to scaffold preparation, comprising the steps of: i) Optimized minimal medium; ii) Incubate for 24 hours at 37 °C and 120 rpm the minimal medium with Bacillus subtilis SP6; iii) Bacillus subtilis SP6 fermented broth; iv) 24hours fermented broth was collected; v) Broth was centrifuged at 8000 rpm for 10 min.; vi) The supernatant of filtrate was extracted with 1:1.5 ml methanol and kept at 4 °C overnight to precipitate; vii) Pelletes were discarded and supernatant collected for allantoin extractionBRIEF DESCRIPTION OF DRAWINGS
[0028] The accompanying illustrations are incorporated into and form a part of this specification in order to aid in comprehending the current disclosure. The pictures demonstrate exemplary implementations of the current disclosure and, along with the description, assist to clarify its fundamental ideas.
[0029] Fig 1 illustrates the schematic representation of methodology for allantoin production to scaffold preparation.
[0030] Fig 2 illustrates the Biophysical characterization of extracted allantoin a. UV spectra b. FTIR spectrum c. HPLC chromatogram d. LCMS spectra.
[0031] Fig 3 illustrates the Photographic image of developed scaffold a. Without allantoin b. With allantoin.
[0032] Fig 4 illustrates the FTIR spectra of biocomposite scaffold.
[0033] Fig 5 illustrates the XRD spectra of biocomposite scaffold.
[0034] Fig 6 illustrates the DSC and TGA thermogram of scaffold a. With allantoin b. Without allantoin.
[0035] Fig 7 illustrates the Antimicrobial studies of scaffold on Gram positive organisms Bacillus subtilis and Staphylococcus aurus.
[0036] Fig 8 illustrates the Wound healing activity of scaffold by scratch assay on L929 fibroblast cell line.
[0037] It should be noted that the figures are not drawn to scale, and the elements of similar structure and functions are generally represented by like reference numerals for illustrative purposes throughout the figures. It should be noted that the figures do not illustrate every aspect of the described embodiment sand do not limit the scope of the present disclosure.
[0038] Other objects, advantages, and novel features of the invention will become apparent from the following detailed description of the present embodiment when taken in conjunction with the accompanying drawings.DETAILED DESCRIPTION OF THE INVENTION
[0039] While the present invention is described herein by way of example using embodiments and illustrative drawings, those skilled in the art will recognize that the invention is not limited to the embodiments of drawing or drawings described and are not intended to represent the scale of the various components. Further, some components that may form a part of the invention may not be illustrated in certain figures, for ease of illustration, and such omissions do not limit the embodiments outlined in any way. It should be understood that the drawings and the detailed description thereto are not intended to limit the invention to the particular form disclosed, but on the contrary, the invention is to cover all modifications, equivalents, and alternatives falling within the scope of the present invention as defined by the appended claim.
[0040] As used throughout this description, the word "may" is used in a permissive sense (i.e. meaning having the potential to), rather than the mandatory sense, (i.e. meaning must). Further, the words "a" or "an" mean "at least one" and the word "plurality" means "one or more" unless otherwise mentioned. Furthermore, the terminology and phraseology used herein are solely used for descriptive purposes and should not be construed as limiting in scope. Language such as "including," "comprising," "having," "containing," or "involving," and variations thereof, is intended to be broad and encompass the subject matter listed thereafter, equivalents, and additional subject matter not recited, and is not intended to exclude other additives, components, integers, or steps. Likewise, the term "comprising" is considered synonymous with the terms "including" or "containing" for applicable legal purposes. Any discussion of documents acts, materials, devices, articles, and the like are included in the specification solely for the purpose of providing a context for the present invention. It is not suggested or represented that any or all these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention.
[0041] In this disclosure, whenever a composition or an element or a group of elements is preceded with the transitional phrase "comprising", it is understood that we also contemplate the same composition, element, or group of elements with transitional phrases "consisting of", "consisting", "selected from the group of consisting of, "including", or "is" preceding the recitation of the composition, element or group of elements and vice versa.
[0042] The present invention is described hereinafter by various embodiments with reference to the accompanying drawing, wherein reference numerals used in the accompanying drawing correspond to the like elements throughout the description. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiment set forth herein. Rather, the embodiment is provided so that this disclosure will be thorough and complete and will fully convey the scope of the invention to those skilled in the art. In the following detailed description, numeric values and ranges are provided for various aspects of the implementations described. These values and ranges are to be treated as examples only and are not intended to limit the scope of the claims. In addition, several materials are identified as suitable for various facets of the implementations.
[0043] The invention discloses a biocomposite film composed of biopolymers chitosan (CS), gelatin (GE) and allantoin (AT) was fabricated through solution casting technique. The functional group interaction of the biocomposite films was inspected through Fourier transform spectrometer (FTIR). The crystallinity and thermal stability of biocomposite films with varied ratios chitosan / gelatin (CS / GE) and allantoin were examined under X-ray diffractometer (XRD) and differential scanning calorimeter and thermogravimetric analysis (DSC and TGA).
[0044] In an embodiment of the present invention, invention relates to a bio composite scaffold composition, comprising: i) chitosan at a concentration of 1% w / v dissolved in 1% v / v acetic acid; ii) gelatin at a concentration of 10% w / v dissolved in double distilled water; iii) allantoin in the amount of 0.5% w / v; and iv) glycerol in the amount of 2 ml per 100 ml of the final mixture.
[0045] In another embodiment of the present invention the method for preparation of composition includes the following steps (i) preparing a culture medium comprising (in g / L): K₂HPO₄ (0.25), NH₄NO₃ (17), MgSO₄·7H₂O (0.25), NaCl (0.02), lactose (12.2), uric acid (2.55), soy peptone (12.79), and FeSO₄·7H₂O (0.00325), (ii) inoculating the medium with 1% v / v of a fresh culture of Bacillus subtilis SP6; (iii) incubating the inoculated medium at 37 °C for 24 hours under shaking conditions at 120 rpm; (iv) centrifuging the fermented broth at 8000 rpm for 10 minutes to obtain a supernatant and a pellet; (v) extracting the supernatant with methanol in a 1:1.5 (broth: methanol) volume ratio and storing at 4 °C overnight to precipitate unwanted compounds; (vi) centrifuging the mixture again under the same conditions and collecting the resulting supernatant; (vii) homogenizing the pellet with methanol to extract additional allantoin and combining this with the supernatant; (viii) evaporating the combined extract using a rotary evaporator at 55 °C to concentrate the allantoin.
[0046] In another embodiment of the present invention the method for the preparation of a allantoin production to scaffold preparation, comprising the steps of; i) Optimized minimal medium; ii) Incubate for 24hours at 37 °C and 120 rpm the minimal - medium with Bacillus subtilis SP6; iii) Bacillus subtilis SP6 fermented broth; iv) 24hours fermented broth was collected; v) Broth was centrifuged at 8000 rpm for 10 min.; vi) The supernatant of filtrate was extracted with 1:1.5 ml methanol and kept at 4 °C overnight to precipitate; vii) Pelletes were discarded and supernatant collected for allantoin extraction.
[0047] In another embodiment of the present invention the biocomposite films reveal improved antibacterial activity against Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus). The in vitro scratch assay shows excellent wound healing properties of biocomposite scaffold containing allantoin on L929 fibroblast cell line. The fibroblast adhesion on the biocomposite film displays enhanced proliferation and viability. These significant biological properties of biocomposite film make it an appropriate candidate for wound dressing application.
[0048] In another embodiment of the present invention the skin is largest organ of the integumentary system in human beings that covers almost human body and functions as protectant of internal tissue and organs from external damage. Being the largest part, it is exposed to many physical, chemical, thermal and microbial harms. Basically, skin is divided into 3 main layers as epidermis, dermis and hypodermis. If any of these skin layers disrupted by any above mentioned potential harmful factors, then wound occurs. If the wound remains untreated, then it will be covered by infection of drug resistant bacteria, that delay the healing process. However, there are few treatments available in severe cases such as, graft rejection, patients donar, but it has certain limitations.
[0049] In another embodiment of the present invention the wound is categorized into 3 types as: (1) superficial wounds, in which only the first layer i.e the epidermis, is damaged, (2) partial-thickness wounds-involves impairment of both epidermis and dermis (3) full-thickness wounds, in which all three layers of skin are damaged. The superficial wound can be naturally healed by the body but in case of partial thickness and full thickness, the body will require time to heal the wound. Healing of wound is complex biological process inclusive of five different stages as: (1) hemostasis, (2) inflammation, (3) migration, (4) proliferation, and (5) maturation or remodeling. If the wounds are treated with suitable biomaterial, it will allow gaseous permeation, moist environment in order clear the wound. This wound healing material must be biocompatible, soft and should be resistant against bacterial infection on application.
[0050] Extraction of allantoin from strainsFor allantoin production, an optimized production medium was used with the following composition:(g L-1), K2HPO4 (0.25), NH4NO3 (17), MgSO4.7H2O (0.25), NaCl (0.02), lactose (12.2), uric acid (2.55), soy peptone (12.79) and FeSO4.7H2O (0.00325). The medium was inoculated with 1% fresh culture of Bacillus subtilis SP6 and incubated at 37 °C for 24hours in a shaking incubator (120 rpm). The 24 hours old fermented broth was centrifuged at conditions 8000 rpm for 10 min. The filtrate was extracted with 1:1.5 ml methanol and kept at 4 °C overnight to precipitate other compounds present in the broth. Centrifuge the respective broth with same conditions and supernatant was collected. The pellets obtained were homogenized with methanol and extracted remaining allantoin. These supernatants were mixed and evaporated in rotary evaporator at 55 °C and the concentrated allantoin was used for future characterization.
[0051] Biophysical characterization of extracted allantoinThe extracted allantoin were employed for UV Vis spectrum determination using Shimadzu spectrophotometer UV-1800 according to the method of Braga R. et al. 2012. Culture broth of 24hr. was centrifuged and the cell debris was removed. The supernatant was taken as a sample and compared with the standard allantoin in the concentration of 0.5 mg / ml. Structural confirmation with respect to the functional groups, stretching was analyzed on FT Nicolet iS10 Mid FTIR spectrometer (Thermo electron scientific, Madison, USA) using Bacillus subtilis SP6 allantoin. Liquid chromatography mass spectrometry (LCMS) analysis was performed on the Bruker Impact HD (Impact II-UHR-ESI-Q-ToF) mass spectrometer and analyzed using Bruker Compass Data Analysis 4.2 software. This data of extracted allantoin compared with the standard allantoin dissolved in methanol and mobile phase as HPLC grade methanol and deionized water (Berthemy A. et al. 1999). Sample preparation for HPLC analysis was done at temperature of 25 ± 2 °C. The standard allantoin was prepared by dissolving in methanol at 0.5 mg / ml concentration. Extracted sample was passed through 0.45 mm nylon filter (Axiva filters) and final volume was adjusted with methanol and stored at 4 °C in the amber vial. Shimadzu unit equipped with degasser DGU-20A 5 R, low-pressure quaternary pump LC 20 AD and SPD- M20A as a photodiode array (PDA) detector. A Nova-Pak C18 column (4 m, 4.6 250 mm) from Waters (Milford, MA) was used for the separation. The mobile phase was 10mM phosphate buffer of pH 4.7. The flow rate was maintained as 1 mL / min and the absorbance detector was set at 220 nm (George S. et al. 2006).
[0052] Development and optimization of allantoin mediated scaffoldFor the composition of biocomposite scaffold, 1 % of chitosan was dissolved in 1% 100 ml of acetic acid. 10 % gelatine prepared by dissolving 10 gm of gelatine in 100 ml double distilled water. The beaker is kept at 50°C for 30 min at stirring condition. Optimization of scaffold preparation was made by taking different concentration of chitosan and gelatine in the ratio as 1:3, 1:1, 3:1 followed by the addition of 0.5% of allantoin and mechanical stirring for 24 hour . One mixture was made by taking 1:1 chitosan and gelatine ratio without addition of allantoin. Addition of 2 ml glycerol was made, which will help as plasticizer. The ultimate mixture was poured into petriplate and kept for drying condition at 48 hours. All the three dried scaffolds were peeled off and stored in vaccume desiccator up to further use.
[0053] Biophysical characterization of biocomposite scaffoldThe synthesized scaffold was characterized by different biophysical techniques like, FTIR, XRD and DSC-TGA analysis. The functional group interaction of the biocomposite scaffold was examined via Fourier transform Infrared spectrometer FTIR (Thermo electron scientific, Madison, USA) with a resolution of 0.5 cm-1 and wavelength from 4000 cm-1- 500 cm-1. The nature of the bio composite films was analyzed by their diffraction patterns using X-ray diffractometer (Bruker D8 advance X-ray diffractometer) at a scanning rate of 4° min-1 from 2θ = 10°-70° with Cu Kα radiation. The thermal behaviour, melting temperature studies of the scaffolds was checked thoroughly by differential scanning colorimeter and thermogravimetric analysis (DSC and TGA). DSC measurement was performed with a SDT Q600 V20.9 Build 20 under 1 °C / min. in nitrogen condition at a flow rate of 50 ml / min.
[0054] Antimicrobial assayThe antimicrobial activity of allantoin mediated scaffold was evaluated against Gram positive and negative microorganisms (Aftab Ahmad et al., 2017). The nutrient agar plates were prepared by using standard protocol and spread with 0.1 mL of 1x108 cells / mL of Bacillus subtilis, Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. The scaffolds were cut in 2mm size and placed on the plates with the use of sterile forcep. The plates were incubated for 24 hours at 37 ºC and next day the zone of inhibition was observed around the scaffold.
[0055] Wound healing properties by scratch assayL929 Fibroblast cells (3 x 105 cells / well) were seeded in 24-well plates to grow in a monolayer for 24hours by using media composition as; DMEM with high glucose (Cat No-11965-092), FBS (Gibco, Invitrogen) Cat No -10270106 Antibiotic - Antimycotic 100X solution. Then a sterile 20-200 μL pipette tip was held vertically to scratch cross in each well. The detached cells were removed by washing with 500 μL PBS and shaking at 500 rpm for 5 min. 500 μL of fresh medium with or without diluted samples was added afterwards and incubated for 72hours. Before the image acquisition, the plate was washed with 500 μL pre-warmed PBS and gently shaken for 30 s. Then, pre-warmed medium or sample was added again and pictures were taken. The scratch closure was monitored and imaged in 24hours intervals using a Keyence BZ-9000 microscope (Keyence, Neu-Isenburg, Germany) at 4 x magnification and 1 / 3700 s exposure time. When the allantoin was extracted from broth, it was explored for the UV spectra. When the standard and samples were scanned simultaneously in the range of 200-600 nm, it was found that the allantoin showed absorption at 220 nm of wavelength along with some spectral interference at wavelength range from 300 to 400 nm. Results were compared with Braga R. et al. with slight difference who found the absorbance range between 230-250 nm for allantoin.
[0056] Biophysical characterization of biocomposite scaffold:The characteristic peak of extracted allantoin was found at 220nm that coincides with the standard allantoin, as shown in fig. 1a. FTIR spectra of scaffolds (a)with allantoin (b) without allantoin is shown in fig.1b The FT-IR spectrum contains broad peaks at 3300 cm-1-3304 cm-1 correspond to the stretching vibrations of O-H and N-H groups related to hydrogen bonding. The sharp absorption peaks at 1640 cm-1 and 1636 cm-1 corresponds to amide-I and C-O groups of amide-II, whereas the bridged oxygen and carbon on the chitosan skeleton showed absorption peaks at 1037 cm-1, 1038 cm-1 respectively. The existence of sharp absorption at 1640 cm-1 corresponds to C-O stretching of amide-I and the peaks at 1548 cm-1,1242 cm-1 relate the N-H bending vibration of amide- II and amide-III in gelatine. In the FT-IR spectrum of allantoin, the characteristic absorption peaks at 3304 cm-1 and 3300 cm-1 refers the symmetric -NH2 and -NH groups in the ring whereas the peaks at 1780 cm-1 and 1163 cm-1-1666 cm-1 corresponds to the carbonyl group (-C=O) on the ring and in amide shows similar absorption peaks. In particular, the absorption peak shift of allantoin from3438 cm-1 to 3265 cm-1 and 1780 cm-1 to 1726 cm-1 clearly indicates the hydrogen bonding of allantoin with CS / GE in the fabricated biocomposite scaffold.
[0057] The XRD patterns of biocomposite scaffold were shown in fig.1c The sharp diffraction peaks of chitosan at 2θ = 20°shows the crystalline nature that arises due to the strong intermolecular attraction of the polymer chains. The moderate crystalline nature of gelatin was evident by the broad diffraction peaks from 2θ = 15°-30° In the case of scaffold, the crystalline behavior of chitosan was found decreased when complexed with gelatin. The shifting of the sharp peak to broad shoulder peak indicates the reduction of crystallinity to the amorphous phase. This change in nature indicates the effectual formation of the polyelectrolytic complex. The allantoin added biocomposite scaffold displays similar broad diffractions ranging from 2θ = 17°-28° with two sharp diffraction peaks at 2θ = 14°and 32° confirmed the presence of allantoin moiety.
[0058] HPLC separations performed at temperature of 25 °C on reversed-phase column with mobile phase 5 mM phosphate buffer (pH 4.7). Fig. 1c showed peak at retention time 3.416 for standard allantoin which coincides with extracted sample (R.T-3.428). The mass spectra of allantoin were obtained by directly filling neat solutions into mass spectrometer via a syringe pump. Under electrospray negative ionization mode, the deprotonated molecular ion [M+H] has m / z value of 158.09 for SP6 (fig.1d) that confirms the presence of allantoin in the sample. In order to achieve baseline separation, a liquid chromatography method carefully developed to ensure accurate analysis.
[0059] Furthermore, the developed scaffold after all the processes, is as shown in fig. 2a represents without allantoin and 2b shows with allantoin scaffolds. FTIR data analysis of developed scaffold (Fig-3) revealed that the, spectrum is highly resembled with standard allantoin. Band wavelength at 3434.6, 3184.86 and 3337.21 represents asymmetric and symmetric stretching of N-H as the bands between the regions of 3450-3160-1 and 3550-3330-1 which corresponds symmetric and asymmetric N-H stretching respectively. C=O stretching observed in the region of 1850-1650-1. The wavelength observed in the region 1650.77 showed the presence of C=O vibrational stretching. The characteristic peak at 777.18 was observed in the IR region which indicates C=O bending out of plane. The C-H stretching was observed at 3049.87-1 and 1524.45 showed C=N structure of purine in the FTIR spectrum.Differential scanning colorimeter was performed for thermal stability determination of the biocomposite scaffold (Fig-5). In graph, gradual decrease in the temperature was noted from 250.95 °C and 301.17 °C resembles to maximum stability of scaffold.
[0060] Antimicrobial studies of scaffoldIn present study, silver nanoparticles of allantoin displayed excellent antimicrobial potential against Gram positive organisms such as Bacillus subtilis and Staphilococcus aureus bacteria. After 24hours incubation of zone of inhibition was observed for the scaffold having allantoin concentration whereas the scaffold without allantoin does not show the zone of inhibition. The figure 6a and 6b showed the antimicrobial activity of biocomposite scaffold against Bacillus subtilis with 5mm, 8mm, 6mm and 2 mm zone of inhibition. Largest zone was observed for B3 scaffold (with allantoin) while smallest zone found in case of B4 scaffold (without allantoin).
[0061] Wound healing activity of scaffold by scratch assay on L929 fibroblast cell lineThe original scratch was made of 1.5 cm on L929 fibroblast cell line for both B3 (with allantoin) and B4 scaffold sample (without allantoin). After addition of the sample, the plates were incubated in CO2 incubator and scratch was observed after each 24hours interval up to complete healing of that patch. The scratch was gradually healing as mentioned in the table. After 72hours incubation the scratch was healed completely (Fig.7). From the figure and observation table it was demonstrated that, B3 sample showed 80 % of wound healing after 72hours incubation whereas B4 possess 73.33 % wound healing efficiency as described in table no 1.Table 1: Observation table of wound healing by scratch assay
[0062] Further, the operations need not be performed in the disclosed order, although in some examples, an order may be preferred. Also, not all functions need to be performed to achieve the desired advantages of the disclosed system and method, and therefore not all functions are required.
[0063] Various modifications to these embodiments are apparent to those skilled in the art from the description and the accompanying drawings. The principles associated with the various embodiments described herein may be applied to other embodiments. Therefore, the description is not intended to be limited to the embodiments shown along with the accompanying drawings but is to be providing the broadest scope consistent with the principles and the novel and inventive features disclosed or suggested herein. Accordingly, the invention is anticipated to hold on to all other such alternatives, modifications, and variations that fall within the scope of the present invention and appended claims.
Claims
1. A bio composite scaffold composition, comprising: i) chitosan at a concentration of 1% w / v dissolved in 1% v / v acetic acid; ii) gelatin at a concentration of 10% w / v dissolved in double distilled water; iii) allantoin in the amount of 0.5% w / v; and iv) glycerol in the amount of 2 ml per 100 ml of the final mixture.
2. The scaffold as claimed in claim 1, wherein the chitosan: gelatin ratio is selected from 1:3, 1:1, or 3:1.
3. The optimized method for the production of allantoin, as claimed in claim 1, wherein the method comprising the steps of: (i) preparing a culture medium comprising (in g / L): K₂HPO₄ (0.25), NH₄NO₃ (17), MgSO₄·7H₂O (0.25), NaCl (0.02), lactose (12.2), uric acid (2.55), soy peptone (12.79), and FeSO₄·7H₂O (0.00325); (ii) inoculating the medium with 1% v / v of a fresh culture of Bacillus subtilis SP6; (iii) incubating the inoculated medium at 37 °C for 24 hours under shaking conditions at 120 rpm; (iv) centrifuging the fermented broth at 8000 rpm for 10 minutes to obtain a supernatant and a pellet; (v) extracting the supernatant with methanol in a 1:1.5 (broth: methanol) volume ratio and storing at 4 °C overnight to precipitate unwanted compounds; (vi) centrifuging the mixture again under the same conditions and collecting the resulting supernatant; (vii) homogenizing the pellet with methanol to extract additional allantoin and combining this with the supernatant; (viii) evaporating the combined extract using a rotary evaporator at 55 °C to concentrate the allantoin.
4. The method as claimed in claim 3, wherein the extracted allantoin is stored at low temperature for future use and characterization.
